BPG is committed to discovery and dissemination of knowledge
Cited by in CrossRef
For: Reshetnyak VI. Concept on the pathogenesis and treatment of primary biliary cirrhosis. World J Gastroenterol 2006; 12(45): 7250-7262 [PMID: 17143938 DOI: 10.3748/wjg.v12.i45.7250]
URL: https://www.wjgnet.com/1007-9327/full/v12/i45/7250.htm
Number Citing Articles
1
Vasiliy I. Reshetnyak, Igor V. Maev. Features of Lipid Metabolism Disorders in Primary Biliary CholangitisBiomedicines 2022; 10(12): 3046 doi: 10.3390/biomedicines10123046
2
Nobuyuki Tamaki, Etsuro Hatano, Kojiro Taura, Masaharu Tada, Yuzo Kodama, Takashi Nitta, Keiko Iwaisako, Satoru Seo, Akio Nakajima, Iwao Ikai, Shinji Uemoto. CHOP deficiency attenuates cholestasis-induced liver fibrosis by reduction of hepatocyte injuryAmerican Journal of Physiology-Gastrointestinal and Liver Physiology 2008; 294(2): G498 doi: 10.1152/ajpgi.00482.2007
3
Filippo Gabrielli, Eleonora Crepaldi, Alessia Cavicchioli, Marco Rivi, Arianna Carmen Costanzo, Carmela Cursaro, Pietro Andreone. Itching for Answers: A Comprehensive Review of Cholestatic Pruritus TreatmentsBiomolecules 2024; 14(10): 1227 doi: 10.3390/biom14101227
4
V. I. Reshetnyak, I. V. Maev. Dyslipidemia and its features in primary biliary cholangitisHealth care of Tajikistan 2023; (1): 119 doi: 10.52888/0514-2515-2023-356-1-119-130
5
Klaas Poelstra, Jai Prakash, Leonie Beljaars. Drug targeting to the diseased liverJournal of Controlled Release 2012; 161(2): 188 doi: 10.1016/j.jconrel.2012.02.011
6
Vasiliy I. Reshetnyak, Igor V. Maev, Tatiana M. Reshetnyak, Sergei V. Zhuravel, Vladimir M. Pisarev. Liver Disease and Hemostasis (Review) Part 2. Cholestatic Liver Disease and HemostasisGeneral Reanimatology 2019; 15(6): 80 doi: 10.15360/1813-9779-2019-6-80-93
7
Benedikte Richter, Anne Roslind, Ulrik Hesse, Jørgen Nordling, Julia Sidenius Johansen, Thomas Horn, Alastair Bierre Hansen. YKL‐40 and mast cells are associated with detrusor fibrosis in patients diagnosed with bladder pain syndrome/interstitial cystitis according to the 2008 criteria of the European Society for the Study of Interstitial CystitisHistopathology 2010; 57(3): 371 doi: 10.1111/j.1365-2559.2010.03640.x
8
I. Grattagliano, P.J. Oliveira, L. Vergani, P. Portincasa. Liver Pathophysiology2017; : 225 doi: 10.1016/B978-0-12-804274-8.00017-5
9
Saeam Shin, In Ho Moh, Young Sik Woo, Sung Won Jung, Jin Bae Kim, Ji Won Park, Ki Tae Suk, Hyoung Su Kim, Mineui Hong, Sang Hoon Park, Myung Seok Lee. Evidence from a familial case suggests maternal inheritance of primary biliary cholangitisWorld Journal of Gastroenterology 2017; 23(39): 7191-7197 doi: 10.3748/wjg.v23.i39.7191
10
Vasiliy Ivanovich Reshetnyak, Igor Veniaminovich Maev. Pathophysiology of biochemical signs of primary biliary cholangitisExploration of Digestive Diseases 2023; : 149 doi: 10.37349/edd.2023.00024
11
Vasiliy Ivanovich Reshetnyak. Primary biliary cirrhosis: Clinical and laboratory criteria for its diagnosisWorld Journal of Gastroenterology 2015; 21(25): 7683-7708 doi: 10.3748/wjg.v21.i25.7683
12
Vasiliy Ivanovich Reshetnyak, Igor Veniaminovich Maev. Mechanism for development of malnutrition in primary biliary cholangitisWorld Journal of Meta-Analysis 2022; 10(3): 81-98 doi: 10.13105/wjma.v10.i3.81
13
Paul‐Henry Koop, Constanze Schwenzer, Jan Clusmann, Mara S. Vell, Julius Jaeger, Wenfang Gui, Christian Trautwein, Alexander Koch, Tony Bruns, Carolin V. Schneider, Kai Markus Schneider. Comorbidities, mortality and metabolic profile in individuals with primary biliary cholangitis—A Phenome‐Wide‐Association‐StudyLiver International 2024; 44(8): 2038 doi: 10.1111/liv.15945
14
Hiroto Tsuboi, Hiromasa Ohira, Hiromitsu Asashima, Sayaka Tsuzuki, Mana Iizuka, Naomi Matsuo, Yuya Kondo, Isao Matsumoto, Takayuki Sumida. Anti‐M3 muscarinic acetylcholine receptor antibodies in patients with primary biliary cirrhosisHepatology Research 2014; 44(14) doi: 10.1111/hepr.12346
15
Neel Deferm, Tom De Vocht, Bing Qi, Pieter Van Brantegem, Eva Gijbels, Mathieu Vinken, Peter de Witte, Thomas Bouillon, Pieter Annaert. Current insights in the complexities underlying drug-induced cholestasisCritical Reviews in Toxicology 2019; 49(6): 520 doi: 10.1080/10408444.2019.1635081